coenzyme-q10 and Graft-vs-Host-Disease

The objective of this study was to determine whether coenzyme Q10 (CoQ10) can reduce the severity of graft versus host disease (GVHD) by inducing regulatory T cells (Tregs). CoQ10 or vehicle was orally administrated once a day for 22 days to mice with GVHD. We measured the alloresponse of the T cells and the GVHD clinical scores. Real-time polymerase chain reaction was used to examine messenger RNA (mRNA) level. Flow cytometry and enzyme-linked immunosorbent assay were used to evaluate protein expression. CoQ10 reduced the T-cell alloresponse and the expression of interferon (IFN)-γ and interleukin (IL)-17. The severity of GVHD and gene expressions of IL-6 and tumor necrosis factor (TNF)-α decreased with CoQ10 treatment. Furthermore, CoQ10 promoted weight gain and survival in GVHD mice. Flow cytometry revealed that CoQ10 dose dependently induced Treg differentiation, but FK506, an immunosuppressive drug, decreased Treg differentiation dose dependently. In conclusion, CoQ10 downregulates the alloreactivity of T cells and reduces GVHD severity, enhancing the differentiation of Tregs.

Topics: Animals; Anti-Inflammatory Agents; Female; Graft vs Host Disease; Humans; Interferon-gamma; Interleukin-17; Interleukin-6; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; T-Lymphocytes, Regulatory; Ubiquinone